Literature DB >> 54231

Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection.

R M Guttman, B A Waisbren.   

Abstract

A factor has been demonstrated in the serum of some patients with chronic Gram-negative infections which specifically blocks bactericidal activity against the infecting organism. Sera with this factor, that had been obtained from patients suffering from chronic Pseudomonas aeruginosa infections, were fractionated by Sephadex G-200 and DEAE-Sephadex column chromatography. Blocking activity was detected in the Sephadex G-200 '7S' peak and eluted from the DEAE column along with the serum IgG. Immunoelectrophoresis studies of this material along with pure IgG showed that the bactericidal blocking factor in these patients was IgG. The blocking factor was specific in its ability to protect bacteria, and could be absorbed from the serum by the particular bacterial strain isolated from the patient. Possible clinical importance of blocking activity by IgG is suggested by the persistent nature of the Ps. aeruginosa infections in these patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 54231      PMCID: PMC1538033     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Fractionation of human blood group antibodies by gel filtration.

Authors:  J KILLANDER; C F HOGMAN
Journal:  Scand J Clin Lab Invest       Date:  1963       Impact factor: 1.713

2.  Fractionation of human plasma proteins by gel filtration and zone electrophoresis or ion-exchange chromatography.

Authors:  B GELOTTE; P FLODIN; J KILLANDER
Journal:  Arch Biochem Biophys       Date:  1962-09       Impact factor: 4.013

3.  Prevalence of antibody to Pseudomonas in normal human sera.

Authors:  S GAINES; M LANDY
Journal:  J Bacteriol       Date:  1955-06       Impact factor: 3.490

4.  Serum bactericidal activity in patients with upper and lower urinary tract infections.

Authors:  P E Gower; P W Taylor; K G Koutsaimanis; A P Roberts
Journal:  Clin Sci       Date:  1972-07       Impact factor: 6.124

5.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

6.  Complement fixation on cell surfaces by 19S and 7S antibodies.

Authors:  T Borsos; H J Rapp
Journal:  Science       Date:  1965-10-22       Impact factor: 47.728

7.  The effect of carbamylation and amidination of rabbit gamma-G-antibody on its ability to fix complement.

Authors:  S Cohen; E L Becker
Journal:  J Immunol       Date:  1968-02       Impact factor: 5.422

8.  Anti-Candida factors in serum and their inhibitors. I. Clinical and laboratory observations.

Authors:  D B Louria; J K Smith; R G Brayton; M Buse
Journal:  J Infect Dis       Date:  1972-02       Impact factor: 5.226

9.  A longitudinal study of serum alpha-1-antitrypsin, alpha-2-macroglobulin, transferrin, immunoglobulins IgG, IgA and IgM, and H- and O-agglutinin titers in children following infection with Salmonella enteritidis.

Authors:  D Wiedermann; D Wiedermannová; J P Vaerman; J F Heremans
Journal:  J Infect Dis       Date:  1970-01       Impact factor: 5.226

10.  ASSOCIATION OF "NATURAL" ANTIBODIES TO GRAM-NEGATIVE BACTERIA WITH THE GAMMA-1-MACROGLOBULINS.

Authors:  J G MICHAEL; F S ROSEN
Journal:  J Exp Med       Date:  1963-10-01       Impact factor: 14.307

View more
  18 in total

1.  Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae.

Authors:  K A Joiner; R Scales; K A Warren; M M Frank; P A Rice
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

Review 2.  Bactericidal and bacteriolytic activity of serum against gram-negative bacteria.

Authors:  P W Taylor
Journal:  Microbiol Rev       Date:  1983-03

3.  Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces.

Authors:  R M Hamadeh; G A Jarvis; U Galili; R E Mandrell; P Zhou; J M Griffiss
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

Review 4.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

5.  Immunological enhancement in the pathogenesis of pyelonephritis.

Authors:  T E Miller; S Burnham; J D North
Journal:  Clin Exp Immunol       Date:  1976-05       Impact factor: 4.330

6.  Complement activation by human IgG antibodies to galactose-α-1,3-galactose.

Authors:  Jens Magnus Bernth Jensen; Nick Stub Laursen; Rasmus Kjeldsen Jensen; Gregers Rom Andersen; Jens Christian Jensenius; Uffe B Skov Sørensen; Steffen Thiel
Journal:  Immunology       Date:  2020-07-14       Impact factor: 7.397

Review 7.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

8.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

9.  Serum bactericidal effect on Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  M J Thomassen; C A Demko
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

10.  Serum-induced lysis of Pseudomonas aeruginosa.

Authors:  T Meshulam; H Verbrugh; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1982-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.